Autophagy manipulation as a strategy for efficient anticancer therapies: possible consequences

Mara Cirone¹²*, Maria Saveria Gilardini Montani¹², Marisa Granato¹², Alessia Garutti³⁴, Alberto Faggioni¹² and Gabriella D’Orazi³⁴*

Abstract

Autophagy is a catabolic process whose activation may help cancer cells to adapt to cellular stress although, in some instances, it can induce cell death. Autophagy stimulation or inhibition has been considered an opportunity to treat cancer, especially in combination with anticancer therapies, although autophagy manipulation may be viewed as controversial. Thus, whether to induce or to inhibit autophagy may be the best option in the different cancer patients is still matter of debate. Here we will recapitulate the possible advantages or disadvantages of manipulating autophagy in cancer, not only with the aim to obtain cancer cell death and disable oncogenes, but also to evaluate its interplay with the immune response which is fundamental for the success of anticancer therapies.

Keywords: Autophagy, Cancer, Immunogenic cell death (ICD), Endoplasmic reticulum (ER stress), Unfolded protein response (UPR), Chloroquine (CQ), Hydroxichloroquine (HCQ), p53, HSF1, NRF2

Background

Macroautophagy, hereafter referred as autophagy, is a bulk degradative process up-regulated under stressful conditions, playing a central role in cellular homeostasis [1]. Autophagy usually helps cancer cells to cope with the shortage of nutrients and with the hypoxic conditions in which they are forced to survive. The modulation of autophagy may play dual roles in tumor suppression and promotion [2, 3]. Its induction is generally considered a valid option in cancer prevention [4], particularly because through a selective form of autophagy, that is the mitophagy, cells ride out of damaged mitochondria, the main producers of reactive oxygen species (ROS) that cause DNA mutations [5]. Autophagy modulators have been used as new anticancer strategy [3, 6], although how to manipulate autophagy to improve the treatment of established cancers is still not clear. Recently, a role of autophagy in the regulation the function of the cells present in the tumor microenvironment such as cancer-associated fibroblasts and immune cells has been highlighted, making the issue of autophagy manipulation even more challenging [7, 8]. Even if many reviews have been published in the last years about autophagy and cancer, here, we will try to recapitulate the multifaceted role of autophagy in cancer therapy and how its manipulation may impact immune response that plays an essential role in tumor regression.

Interplay between autophagy and immune system in anticancer therapies

The inhibition of autophagy has been pursued as a possible avenue to treat cancer, considering that autophagy represents a mechanism of adaption to stress especially when exacerbated by chemotherapies [9]. Indeed, excluding the rare and debated cases in which chemotherapies may induce an autophagic cell death [10], autophagy is triggered along with apoptosis as a pro-survival mechanism, as also evidenced by our studies [11–16]. Based on this knowledge, in vivo studies have started to employ autophagy inhibitors, such as...
inhibitors of the lysosomal protease and anti-malaric drugs, Chloroquine (CQ) or Hydroxichloroquine (HCQ), to treat cancer, more often in combination with chemotherapies able to induce autophagy [17–19]. Such combinations, mainly used to treat cancer in xenograft mouse models, have registered some successes in controlling tumor growth and prolonging host survival [20–22]. However, in order to avoid tumor rejection, immune deficient mice have been used for these experiments, thus cutting out the possibility to explore the direct and indirect role of autophagy inhibitors on the cells of the immune system [8]. Moving forward, the impact of autophagy inhibition in combination with chemotherapy has been explored also in immune competent mice. Surprisingly, these studies demonstrate that the depletion of essential autophagy-relevant gene products such as autophagy related (ATG) 5 or beclin 1 (BECN1) [1–3], although increase the cancer cytotoxic effect of therapy in vitro and in vivo in immune deficient mice, reduce the efficacy of radiotherapy or chemotherapy in immune competent mice [23] (Fig. 1a). These findings were somehow surprising because it raised many questions about the likely key role of the immune response for efficient anticancer therapies in the course of autophagy manipulation. In the mean time, several molecules exposed on the cancer cell surface or released by dying cancer cells upon chemotherapies, were discovered to elicit an immunogenic cell death (ICD) able to activate the immune system [24, 25]. In this regard, our studies identified Calreticulin and Heat Shock Protein (HSP) 90 as the Damage Associated Molecular Patterns (DAMPs) exposed on the surface of dying lymphoma cells treated by Bortezomib, and the CD91 as the receptor molecule involved in their recognition by dendritic cells (DCs) [26, 27]. DCs are powerful antigen-presenting cells (APCs) that play a pivotal role initiating a specific immune response and in the eradication of apoptotic cancer cells by mediating the cross-presentation of tumor antigens to the cytotoxic T cells, therefore, their function is fundamental for immune response activation [28]. Further investigations have highlighted that autophagy strongly contributes to the immunogenicity of cell death, promoting the release of adenosine triphosphate (ATP), a DAMP

![Fig. 1a](image-url) Schematic representation of blockade of chemotherapies-induced autophagy and the relative outcome in tumor xenografts of immune deficient mice or immune competent mice models. **b** Schematic representation of immunogenic cell death (ICD) induced by autophagy. Dying cancer cells because chemotherapies activate autophagy that allows ATP release and calreticulin exposure that favor the activation of the immune response.
that plays a key role in immune cell activation [23, 29, 30] (Fig. 1b). These findings could explain why the combination of chemotherapy with autophagy inhibitors did not give the expected result in tumor models in immune competent mice, as it now clear enough that the contribution of the immune response is essential for a successful anti-tumor therapy.

Despite the unclear role of autophagy inhibition in improving the outcome of chemotherapies, clinical trials have started to use CQ or HCQ, mainly in combination with chemotherapies, to treat cancer patients [9, 31, 32]. The results so far obtained have been quite disappointing and the treatment failure may be explained also by the reduction of autophagy-induced ATP release, and by the fact that these anti-malaric drugs inhibit lysosomal acidification, thus may affect many other important cellular processes other than autophagy [33]. Moreover, when systemically administrated, CQ or HCQ may have several side effects [34] and act on immune cells suppressing their functions, i.e. stimulating the T regulatory cells (Treg) [35], altering class II antigen presentation or cross-presentation by DCs [36] or even impairing DC formation, all mechanisms inducing suppression of the immune response [37]. Interestingly, the reduction of autophagy in monocytes represents a strategy through which the human oncogenic gammaherpesviruses Epstein-Barr virus (EBV) and Kaposi’s sarcoma-associated herpesvirus (KSHV) alter monocyte differentiation into DCs, to escape from immune recognition, as also demonstrated by our studies [38–40]. In line with the evidences indicating that autophagy is required for an effective immune response and for the activation of immune system in the course of anticancer chemotherapies, we have found that autophagy inhibitor CQ abrogates the cytotoxic effect of curcumin against breast cancer in immune competent mice while increases it in immune deficient mice [40]. These findings point out, once again, that autophagy inhibition reduces the success of anticancer therapy in the presence of a functional immune system. Moreover, this study evidenced that CQ counteracts the curcumin down-regulation of Hypoxia Inducing Factor (HIF)-1, the main effector of cellular response to hypoxia involved in cancer progression and chemoresistance [41], and that sustained HIF-1 activation correlates with higher infiltrate of immune suppressive Treg cells in the tumor bed of curcumin plus CQ-treated mice [40]. In agreement, previous studies have shown that HIF-1 could be degraded through the lysosomal route [42, 43], suggesting that autophagy inhibition by CQ may interfere with HIF-1 degradation promoted by curcumin and sustain its oncogenic function for tumor progression.

**Autophagy and oncogenes degradation**

Here we come to another important and probably under-estimated role of autophagy in cancer, namely its capacity to degrade molecules involved in tumor survival, progression or chemoresistance, such as oncogenes or mutated oncosuppressor genes. At this purpose, our and other’s laboratories have shown that some mutant (mut) p53 proteins, that acquire pro-oncogenic functions (gain-of-function, GOF) [44], may undergo degradation through autophagy [45–48] or through chaperone-mediated autophagy (CMA) [49], both inhibited by the use of CQ and HCQ. While wild-type p53 has been reported to induce autophagy, mutp53 has been reported to reduce autophagy, especially when it is localized in the cytoplasm as a self-protective mechanism [16, 50], or through stimulation of the mammalian target of rapamycin (mTOR) pathway, sustaining tumor progression [51, 52]. Interestingly, mutp53 may activate HIF-1 [53] and it could be speculated that the inhibition of autophagy by mutp53 might promote HIF-1 activation, given that HIF-1 is degraded through the lysosomal route [42, 43]. The best described mechanism of mutp53 GOF is its ability to interact with transcription factors, remodelling the cancer cell transcriptome and proteome in such a way to support cancer cell survival, tumor progression, invasion, metastasis and chemoresistance [54]. Thus, other than interacting with HIF-1, mutp53 may interact and contribute to the activation of Heat Shock Factor 1 (HSF1) [55], a transcription factor that maintains cellular homeostasis by stress-mediated induction of HSP and coordinates cellular processes critical for malignancy such as metastasis and inhibition of apoptosis [56, 57]. Interestingly HSF1, activated in response to proteotoxic stress and basally activated in cancer cells [55], has been shown to be degraded through autophagy [58]. HSF1 can engage a cross-talk with nuclear factor erytroid 2 like (NRF2/NFE2L2) [59], the main transcription factor regulating the antioxidant response [60]. HSF1 and NRF2 regulate autophagy [60] and both promote the transcription of sequestosome 1/p62 (SQSTM1/p62) [59], a protein that is indeed up-regulated in stressful conditions. SQSTM1/p62 is mainly degraded through autophagy and thus is considered a marker to evaluate the completeness of the autophagic flux, as it accumulates when autophagy is inhibited [1]. SQSTM1/p62 may control a variety of other cellular processes involved in cell death or survival decision [61, 62]. Importantly, SQSTM1/p62 may stabilize NRF2, by degradation of NRF2 negative regulator kelch like ECH associated protein (Keap)1, thus linking autophagy to the anti-oxidant response [63] (Fig. 2). NRF2 is another transcription factor with which mutp53 may interact, promoting the transcription of pro-survival antioxidant enzymes [54] and this interplay with oncogenes further sustain tumor progression [64]. Included in the list of oncogenic transcription factors interconnected with mutp53 [65] and regulated by autophagy there is also c-myc, thus our studies showed that autophagy
contributes to its degradation in Burkitt’s lymphoma cells treated with quercetin [66]. Furthermore, other oncogenic proteins such as K-RAS [67] and PML/RARA [68] can be degraded through autophagy and interact with mutp53 [69, 70] (Fig. 2). It is somehow intriguing that the expression of mutp53 and of many other oncogenic proteins interconnected with it may be regulated by autophagy and/or may regulate autophagy. The number of these oncogenic proteins is increasing, suggesting that other molecules involved in cancer development, survival and progression could come out to be regulated by autophagy. Considering that the oncogenic pathways may activate each other and that such cross-talk, besides cancer cells, may influence the function of immune cells, many other important effects of autophagy manipulation could be discovered. For example, it has been recently shown that PI3K/AKT/mTOR pathway, the master regulator of autophagy, often activated in cancer cells, may be involved in the up-regulation of the immune checkpoint inhibitor PD-L1 [71] whose expression on the tumor cells, by interacting with PD-1 on T cell surface, induces T cell exhaustion [72, 73]. It will be important to further explore the interplay between autophagy and PD-L1 expression, for example in cancer cells harboring mutp53, whose expression inhibits autophagy and activates mTOR.

**Interplay between autophagy, endoplasmic reticulum (ER) stress and unfolded protein response (UPR)**

Last but not least, it must be considered the interplay between autophagy, Endoplasmic Reticulum (ER) stress and Unfolded protein response (UPR) in the regulation of cancer cell survival [74]. Many reviews have been recently published elucidating the role of ER stress, UPR and autophagy in cancer [75–78]. The ER stress is induced by several cellular stresses that activates UPR to reduce the amount of misfolded proteins through ubiquitin-proteasome-dependent ERAD (ER-associated degeneration) and autophagy activation that restores ER homeostasis [75, 76, 78]. Under prolonged and irreversible ER stress, cells undergo apoptosis (Fig. 3) [75, 76, 78]. The UPR is indeed a transcriptional program that induces adaptation, survival, transformation, angiogenesis and resistance to cell death through three main sensors localized at the ER membrane: the inositol-requiring enzyme 1α (IRE1α), PKR-like ER kinase (PERK) and the activating transcription factor 6 (ATF6) [79]. IRE1α trans-autophosphorylation induces cleavage of XB1 leading to expression of the transcription factor XBP1s that regulates the expression of genes related with folding, entry of proteins to the ER, ER-associated degradation (ERAD) and biogenesis of ER and Golgi; PERK activation favours the phosphorylation of eIF2α (eukaryotic translation initiation factor 2α) and the selective translation of ATF4 (activating transcription factor 4), regulating the expression genes involved in folding, oxidative stress and amino acid metabolism; ATF6 translocates to the nucleus to induce the transcription of genes involved in ER homeostasis, and ERAD components (Fig. 3) [75–79]. ER stress is known to promote autophagy, and although the interplay between them remains still to be fully elucidated, the activation of UPR arms eIF2α and IRE1 have been reported to trigger autophagy [76, 80]. On the other hand, the inhibition of autophagy may exacerbate ER stress [80], altering the activation of UPR arms, leading for example to the up-
regulation of the pro-apoptotic molecule C/EBP homologous protein (CHOP). Of note, CHOP can activate Cyclooxigenase (COX)-2 that in turn may promote the release of Prostaglandin (PG) E2, a DAMP that induces immune suppression [81, 82]. Moreover, ER stress in cancer cells promotes the release of factors such as ROS that may transfer ER stress from tumor cells to the immune cells, such as DCs, in the tumor environment. This event may activate the endoribonucleasic activity of IRE1α in DC, inducing the splicing of X-box binding protein (XBP1s). The formation of XBP1s may in turn promote an abnormal accumulation of peroxidized lipids, strongly impairing the immune function of DCs [83]. XBP1s’ activation and the up-regulation of CHOP have been also observed in myeloid suppressive DCs (MDSCs) present in the tumor environment [84]. Interestingly, it has been reported that ER stress can be transferred from cancer cells also to macrophages, promoting their polarization into M2 phenotype [85], tumor-associated macrophages that support instead of fighting tumor [86].

Conclusions
Based on the findings reported by the majority of studies in this field, it seems that autophagy induction rather than autophagy inhibition could be exploited to improve the outcome of cancer treatment, at least in immune competent hosts. Therefore, nutraceuticals, exercise, calorie restriction or calorie restriction mimetics (such as metformin), all able to induce autophagy, are being considered as a possible alternative avenue to treat cancer in combination with chemotherapies [87, 88]. In addition, just to make this complicated field more complicated, it is emerging that inhibiting autophagy specifically in cancer cells may enhances the abscopal response to radiation therapy, that is, the ability of localized radiation to trigger systemic antitumor effects [89, 90], thus suggesting that selective autophagy inhibition in cancer cells and systemic induction of autophagy could be combined to improve the outcome of anti-cancer therapy. Considering the role of autophagy in regulating the expression of oncopenes and modulating the function of the cells of the tumor environment such as fibroblasts and immune cells, more questions than answers have been raised by this review. Therefore, more investigations are needed to further clarify the possible consequences of autophagy manipulation in cancer therapy.

Abbreviations
APCs: Antigen-presenting cells; ATG5: Autophagy related 5; ATP: Adenosine triphosphate; BECN1: Beclin 1; CHOP: C/EBP homologous protein; COX-2: Cyclooxigenase-2; CQ: Chlororoquine; DAMPs: Damage Associated Molecular Patterns; DCs: dendritic cells; EBV: Epstein-Barr virus; EIF2α: Eukaryotic translation initiation factor 2α; ER: Endoplasmic Reticulum; HCO: Hydroxichloroquine; HIF-1: Hypoxia Inducible Factor-1; HSF1: Heat Shock Factor 1; HSIP90: Heat shock protein 90; IC: Immunogenic dell death; Keap1: kelch like ECH associated protein 1; KSHV: Kaposi’s sarcoma-associated herpesvirus; MDSCs: myeloid suppressive DCs; mTOR: Mammalian target of rapamycin; NRF2: Nuclear factor erytroid 2 like; PGE2: Prostaglandin E2; ROS: Reactive oxygen species; SQSTM1: Sequestosome 1; UPR: Unfolded protein response; XBP1: X-box binding protein 1

Acknowledgements
We thank all the people in the lab for critical discussion.

Authors’ contributions
Conception and design: MC, GD; Writing: MC, GD; revision of the manuscript: MSGM, MG, AG, AF. All authors read and approved the final manuscript.

Funding
The research in M.C.’s lab within the realm of this manuscript is funded by Istituto Pasteur Italia Fondazione Cenci Bolognetti and by Fondi Ateneo; in G.D.’ lab is funded by AIRC and by Fondi Ateneo.

Availability of data and materials
All data analysed in this study are included in this published article.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Experimental Medicine, “Sapienza” University of Rome, Rome, Italy. 2Laboratory affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Rome, Italy. 3Department of Medical Science, University G. D’Annunzio, 66013 Chieti, Italy. 4Department of Research, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.
References

1. Klonowski Dj, Abdelmohsen K, Abe A, Abdest M, Abdelbch A, Acevedo Arizena A, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016;12:211–222.

2. Yun CW, Lee SH. The roles of autophagy in Cancer. Int J Mol Sci. 2018;19:3466.

3. Udristioiu A, Nica-Badea D. Autophagy dysfunctions associated with cancer cells and their therapeutic implications. Biomed Pharmacother. 2019;115:106992.

4. Galluzzi L, Bravo-San Pedro JM, Kroemer G. Defective autophagy initiates malignant transformation. Mol Cell. 2016;62:473–4.

5. Plopet-Pérez L, Despouy G, Delage-Mourroux R, Boyer-Gauttard M. Interplay between ROS and autophagy in cancer cells, from tumor initiation to cancer therapy. Redox Biol. 2015;4:184–92.

6. Jiang J, Li H, Qaed E, Zhang J, Song Y, Wu R, et al. Salinomycin, as an autophagy modulator—-a new avenue to anticancer: a review. J Exp Clin Cancer Res. 2018;37:26.

7. Yan Y, Chen X, Wang X, Zhao Z, Hu W, Zeng S, et al. The effects and the mechanisms of autophagy on the cancer-associated fibroblasts in cancer. J Exp Clin Cancer Res. 2019;38:171.

8. Jiang GM, Tan Y, Wang H, Peng L, Chen HT, Meng XJ, et al. The relationship between autophagy and the immune system and its applications for tumor immunotherapy. Mol Cancer. 2019;18:17.

9. Marinovic M, Sprung M, Buljubasic M, Novak I. Autophagy modulation in cancer: current knowledge on action and therapy. Oxidative Med Cell Longev. 2018;2018:8023821.

10. Fulda S. Autophagy in cancer therapy. Front Oncol. 2017;7:128.

11. Gtanato M, Santarelli R, Lotti LV, Di Renzo L, Gonnella R, Garufi A, et al. JNK and macroautophagy activation by bortezomib has a pro-survival effect in primary effusion lymphoma cells. PLoS One. 2013;8:e59565.

12. Gtanato M, Chiozzi B, Fiardil MR, Lotti LV, Di Renzo L, Faggioni A, et al. Tiroside kinase inhibitor tyrphostin AG490 triggers both apoptosis and autophagy by reducing HSF1 and Mcl-1 in PEL cells. Cancer Lett. 2015;366:191–7.

13. Gtanato M, Rizziello C, Gilardini Montani MS, Cuomo L, Vitillo M, Santarelli R, et al. Quercetin induces apoptosis and autophagy in primary effusion lymphoma cells by inhibiting PI3K/AKT/mTOR and STAT3 signaling pathways. J Nutr Biochem. 2017;41:124–36.

14. Masu A, Hamada M, Kameyama H, Wakabayashi K, Takasu A, ImaI T, et al. Autophagy as a survival mechanism for squamous carcinoma cells in endogenous Luc-mediated apoptosis. PLoS One. 2016;11:e0162786.

15. Gtanato M, Gilardini Montani MS, Santarelli R, D’Ottoglie G, Faggioni A, Crone M, Apigenin, by activating p53 and inhibiting STAT3, modulates the balance between pro-apoptotic and pro-survival pathways to induce PEL cell death. J Exp Clin Cancer Res. 2017;36:167.

16. Garufi A, Pistritto G, Baldari S, Tioietta G, Crione M, D’Orazio G. p53-dependent PUMA to DRAM antagonistic interplay as a key molecular switch in cell-fate decision in normal/high glucose conditions. J Exp Clin Cancer Res. 2017;36:126.

17. Li J, Hou N, Faried A, Tsuutsui S, Kuwano H. Inhibition of autophagy augments 5-fluorouracil chemotherapy in human colon cancer in vitro and in vivo model. Eur J Cancer. 2010;46:1900–9.

18. Levy JMM, Towers CG, Thorburn A. Targeting autophagy in cancer. Nat Rev Cancer. 2017;17:528–42.

19. Verbaanderd C, Maes H, Schaaf MB, Pantziarka P, Sukhatme VP, Van Etten LA, et al. Repurposing drugs in oncology (ReDo)-chloroquine and hydroxychloroquine as anti-cancer agents. Eancers. 2017;11:781.

20. Jia L, Wang J, Wu T, Wu J, Ling J, Cheng B. In vitro and in vivo antitumor effects of chloroquine on oral squamous carcinoma cell. Mol Med Rep. 2017;15:5779–86.

21. Zhao XG, Yang XY, Liu DY, Lei DP, Jin T, et al. Chloroquine-enhanced efficacy of cisplatin in the treatment of hypopharyngeal carcinoma in xenograft mice. PLoS One. 2015;10:e0126147.

22. Chou HL, Lin YH, Liu W, Wu CY, Li RN, Huang HW, et al. Combination therapy of chloroquine and C22-ceramide enhances cytotoxicity in lung cancer H460 and H1299 cells. Cancers. 2019;11:370.
involves p53 activation in wild-type p53-expressing colorectal cancer cells. J Exp Clin Cancer Res. 2015;34:87.

49. Väkiäjärvi-Norberg H, Kim M, Xia HG, Iwanicki MP, Olfenbuttel D, Colloff JL, et al. Chaperone-mediated autophagy degrades mutant p53. Genes Dev. 2013;27:1718–30.

50. Marselli E, Tasdemir E, Mäurer MC, Galluzzi L, Kepp O, Crivello A, et al. Mutant p53 protein localized in the cytosol inhibits autophagy. Cell. 2008;135:3056–61.

51. Cordani M, Oppici E, Dando I, Butturini E, Dalla Pozza E, Nadal-Serrano M, et al. Mutant p53 proteins counteract autophagic mechanism sensitizing cancer cells to mTOR inhibition. Mol Oncol. 2016;10:1088–29.

52. Dando L, Pacchiari R, Pozza ED, Cataldo I, Bruno S, Conti P, et al. UCP2 inhibition induces ROS/Akt/mTOR axis role of GADPH nuclear translocation in genipin/everolimus anticancer synergism. Free Radic Biol Med. 2017;113:176–89.

53. Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, et al. Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. Cell Death Diff. 2018;25:486–541.

54. Mantovani F, Collavini L, Del Sal G. Mutant p53 as a guardian of the cancer cell. Cell Death Diff. 2019;26:199–212.

55. Li D, Yallowitz A, Ozog L, Marchenin N. A gain-of-function mutant p53-HSF1 feed forward circuit governs adaptation of cancer cells to protoxic stress. Cell Death Dis. 2014;5:e194.

56. Home T, Jensen RA, Rao R. Heat shock factor 1 in protein homeostasis and oncogenic signal integration. Cancer Res. 2015;75:907–12.

57. Gomez-Pastor R, Burchiel ET, Theile DJ. Regulation of heat shock transcription factors and their roles in physiology and disease. Nat Rev Mol Cell Biol. 2018;19:14–19.

58. Kim E, Sakata K, Liao FF. Bidirectional interplay of HSF1 degradation and UPR activation promotes tau hyperphosphorylation. PLoS Genet. 2017;13:e1006849.

59. Dayalan Naidu S, Kostov RV, Dikovskaya D, Gaurilcikaite E, Knatko EV, Healy ZR, Mohan H, et al. Transcription factors NRF2 and HSF1 have opposing functions in genipin/everolimus anticancer synergism. Front Oncol. 2016;6:12.

60. Dayalan Naidu S, Dikovskaya D, Gaurilcikaite E, Knatko EV, Healy ZR, Mohan H, et al. Transcription factors NRF2 and HSF1 have opposing functions in genipin/everolimus anticancer synergism. Front Oncol. 2016;6:12.

61. Mathew R, Karp CM, Beaudoin B, Vuong N, Chen G, Chen HY, et al. Autophagy suppresses tumorigenesis through elimination of p62. Cell. 2000;103:1062–75.

62. Moscat J, Diaz-Meco MT. p62 at the crossroads of autophagy, apoptosis, and cancer. Cell. 2009;137:1001–2.

63. Katsumi Y, Ichimura Y, Kornsma M, Matsuoka M. p62/SQSTM1 functions as a signaling hub and an autophagy adaptor. FEBS J. 2015;282:4672–8.

64. D’Orazio G, Grone M. Mutant p53 and cellular stress pathways: a criminal alliance that promotes cancer progression. Cancers (Basel). 2019;11:614.

65. Liao P, Zeng SX, Zhou X, Chen T, Zhou F, Cao B, et al. Mutant p53 gains its function via c-Myc activation upon CDK4 phosphorylation at serine 249 and consequent PIN1 binding. Mol Cell. 2017;68:1134–46.

66. Granato M, Rizzello C, Romeo MA, Yadav S, Santarelli R, D’Orazio G, et al. Concomitant reduction of c-Myc expression and PI3K/AKT/mTOR signaling by quercetin induces a strong cytotoxic effect against Burkitt’s lymphoma. Int J Biochem Cell Biol. 2016;79:393–400.

67. Kohli L, Kaza N, Cork T, Byer SJ, Brossett NM, Klocke BJ, et al. 4-Hydroxytamoxifen induces autophagic death through K-Ras degradation. Cancer Res. 2013;73:4395–405.

68. Isakson P, Bjoraz M, Boe SQ, Simonsen A. Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein. Blood. 2010;116:2324–31.

69. Bailey JM, Hendley AM, Laffer J, Pruski MA, Jones NC, Alina J, et al. p53 mutations cooperate with oncogenic Kras to promote adenocarcinoma from pancreatic ductal cells. Oncogene. 2016;35:4282–8.

70. Haupt S, Raghur D, Haupt Y. Mutant p53 drives Cancer by subverting multiple tumor suppression pathways. Front Oncol. 2016;6:12.

71. Lastwika KJ, Wilson W 3rd, Li QK, Norris J, Xu H, Ghazarian SR, et al. Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer. Cancer Res. 2016;76:2327–38.

72. Thommen DS, Koeler VH, Hertzig P, Roller A, Trefny M, Dimeloe S, et al. A transcriptionally and functionally distinct PD-(+) CD8(+) T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat Med. 2018;24:994–1004.